Balx.Ns

# BALX.NS: Business Summary

BALX.NS operates in the Pharmaceuticals & Medical Research industry, focusing on the development, manufacturing, and distribution of pharmaceutical products.

# BALX.NS: Classification Summary

BALX.NS is classified under the Healthcare economic sector, within the Pharmaceuticals & Medical Research business sector, with a classification confidence of 0.92.

# BALX.NS: Narrative

BALX.NS has a liquidity ratio of 4.45, indicating a strong ability to meet short-term obligations, though its operating cash flow is negative at -350,034,000 INR, suggesting potential cash flow constraints. The company's debt-to-equity ratio is 0.23, which is relatively low, indicating a conservative capital structure. The return on equity of 10.82% and return on assets of 8.08% suggest that the company is generating reasonable returns on its equity and asset base.

In terms of profitability, BALX.NS reported a net income of 250,703,000 INR and an operating income of 354,129,000 INR, with a gross profit of 1,268,216,000 INR. These figures indicate a solid performance in terms of profitability, though the company's operating cash flow is negative, which may affect its ability to sustain operations without external financing.

The company's revenue is concentrated in a single segment, with no disclosed geographic diversification. This lack of diversification may expose the company to higher risks in the event of market or regulatory changes in its primary market.

BALX.NS has a free cash flow of 58,457,000 INR and a capital expenditure of -211,191,000 INR, indicating that the company is investing in its operations. The company's outlook for the current fiscal year is positive, with expected growth in revenue and profitability.

The company faces a medium liquidity risk due to its negative operating cash flow and a low dilution risk. The company's risk assessment indicates that it is not currently facing significant dilution pressures, but the negative net cash position after subtracting total debt is a key flag to monitor.

Recent events include the company's financial performance and capital structure adjustments. The company has not disclosed any significant recent filings or transcripts that would indicate major changes in its operations or strategy.

# BALX.NS: Key Takeaways

- BALX.NS has a strong liquidity position with a current ratio of 4.45. - The company's debt-to-equity ratio is 0.23, indicating a conservative capital structure. - BALX.NS reported a net income of 250,703,000 INR and an operating income of 354,129,000 INR. - The company's free cash flow is 58,457,000 INR, indicating a positive cash flow after capital expenditures. - BALX.NS faces a medium liquidity risk and a low dilution risk. - The company's revenue is concentrated in a single segment, which may increase its exposure to market risks.

# BALX.NS: Rationales

# BALX.NS: Inversion (DS-6)

# BALX.NS: Self Scoring (§A.8)